



Press release August 21, 2013

Pilot study with Tigran™ PTG shows bone formation without osteoclastic activity

In a pilot study of two patients with bilateral sinus augmentation, deproteinized bovine particulates (Bio-Oss®) were placed as bone substitute material on one side and Tigran's nonresorbable Porous Titanium Granules (PTG) on the other side. After 9 months, biopsies were performed for histologic and 3-dimensional analysis. Both types of bone substitutes were integrated into the bone. Multinuclear cells (responsible for bone resorption) were observed in the Bio-Oss biopsies, but not in the PTG biopsies. The study has been published in the August issue of the journal *Implant Dentistry*.

Vandeweghe S, Leconte C, Ono D, Coelho PG, Jimbo R. Comparison of Histological and Three-Dimensional Characteristics of Porous Titanium Granules and Deproteinized Bovine Particulate Grafts Used for Sinus Floor Augmentation in Humans: A Pilot Study. *Implant Dent*. 2013 Aug;22(4):339-43.

Arve Nilsson, acting CEO and director of Tigran Technologies, said: I am very pleased with the result, but also with that the authors emphasize the importance of biocompatibility and porosity of bone substitute materials.

For more information, please contact:

Arve Nilsson, acting CEO
Tigran Technologies
+46 768 60 77 10
a.nilsson@tigran.se
www.tigran.se

About Tigran Technologies

Tigran Technologies AB (publ) is a dental development company based in Sweden. With its products Tigran™ PTG, Tigran™ PTG White and Tigran™ PeriBrush Tigran™, Tigran contributes to modern and effective treatment methods for dental clinicians and better treatment results for patients.

Tigran runs an extensive development program and has several published, submitted and on-going experimental and clinical studies. Its products are CE marked and covered by a comprehensive patent portfolio.

'Tigran' is a registered trademark.

Tigran Technologies AB (publ) is since November 2008 listed on AktieTorget.

